Lyka Labs Ltd - LYKA LABS Share Price

Sector: Pharmaceuticals | ISIN: INE933A01014
₹ 115.55 (4.15%) icon29 Sep, 2023, 3:57:34 PM
Open
₹ 110.15
Prev. Close
₹ 110.95
Turnover(lac)
₹ 455.88
Day's High
₹ 118.00
Day's Low
₹ 110.15
52 Wk High
₹ 155.90
52 Wk Low
₹ 88.50
Book Value
₹ 27.42
Face Value
₹ 10.00
Mkt. Cap (Cr.)
₹ 382.35
P/E
0.00
EPS
0.00
Div. Yield
0.00

Lyka Labs Ltd KEY RATIOS

sector: Pharmaceuticals

  • CMP

    as on 9/29/2023 3:57:34 PM

    ₹ 115.55 4.60 4.15
  • Open
  • ₹ 110.15
  • Prev. Close
  • ₹ 110.95
  • Turnover(Lac.)
  • ₹ 456
  • Day's High
  • ₹ 118
  • Day's Low
  • ₹ 110.15
  • 52 Week's High
  • ₹ 155.9
  • 52 Week's Low
  • ₹ 88.5
  • Book Value
  • ₹ 27.42
  • Face Value
  • ₹ 10
  • Mkt Cap (₹ Cr.)
  • 382.35
  • P/E
  • 0
  • EPS
  • 0
  • Divi. Yield
  • 0

Lyka Labs Ltd Corporate Actions

26 Jul , 2023

12:00 AM

26 Jul , 2023

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

10 Jul , 2023

12:00 AM

AGM

Announcement date: 10 Jul , 2023

View Details

16 May , 2023

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

11 Apr , 2023

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

08 Mar , 2023

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

21 Jan , 2023

12:00 AM

31 Jan , 2023

12:00 AM

31 Jan , 2023

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

18 Jan , 2023

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

01 Nov , 2022

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

01 Nov , 2022

12:00 AM

10 Jul , 2023

12:00 AM

BookCloser

View Details

Lyka Labs Ltd News and Update

Image not found
  • 27 September, 2023 |
  • 8:33 PM

A 51% stake in TCNS Clothing has been acquired by Aditya Birla Fashion Retail Ltd (ABFRL), making it a promoter of the women's clothing company.

Image not found
  • IIFL News Service |
  • 26 September, 2023 |
  • 8:31 PM
Image not found
Article Image
  • IIFL News Service |
  • 22 September, 2023 |
  • 8:26 PM

Invest wise with Expert advice

mobile icon
  • Open Demat with exclusive Advice & Services
  • Get a dedicated Relationship Manager to help you grow your wealth
  • Exclusive advisory on 20+ trading & wealth based investment options
  • One tap Investments, Automated trading & much more
  • Minimum 1 lakh margin required

Lyka Labs Ltd SHAREHOLDING SNAPSHOT
29 September , 2023 | 09:44 PM

PROMOTER - TOTAL54.58%

Indian: 54.58%

Foreign: 0%

NON-PROMOTER - TOTAL 45.42%

Institutions: 0.58%

Non-Institutions: 44.85%

CUSTODIES - 0.00%

Custodies: 0.00%

See More Details
ad IconAd Image

Lyka Labs Ltd FINANCIALS

Lyka Labs Ltd PEER COMPARISON

Figures of Market Capital(Mar Cap), Quaterly Net Profit(NP Qtr) and Quaterly Sales(Sales Qtr) are in ₹ Cr.View All Peer Comparison

MORE ABOUT Lyka Labs Ltd

  • KUNAL NARENDRA GANDHI
  • Chairman & MD & CEO
  • Sandeep P Parikh
  • Non-Exec. & Independent Dir.
  • Yogesh B Shah
  • Executive Director & CFO
  • Dhara P. Shah
  • Non-Exec. & Independent Dir.
  • Kishore P Shah
  • Company Sec. & Compli. Officer
  • Babulal Jain
  • Independent Director
  • Prashant Godha
  • Director
  • Shashil Mendonsa
  • Director

Summary

Initially manufacturing formulations, Lyka Labs brought bulk drugs into its operational fold by amalgamating Lyphin Chemicals Pvt Ltd with itself in Apr. 83. It also added a range of ayurvedic and animal health care products over the years. In 1990, it diversified into marketing medical and diagnostic equipment and instruments of Bekton Dickinson, US; Airsep Corporation, US; Coloplast, Denmark; and Terumo Corporation, Japan. Lyka Exports is the subsidiary of the company. The company offers a broad range of antibiotics used as life-savers and to treat minor infections. It has a fairly widespread product base with tropical steroids for skin disorders, anti-cancer products, cardio-vascular drugs and anti-inflammatory products. Lyka introduced, in India, cough lozenges containing dextromethorphan hydrobromide (DMR), favoured internationally as an effective and safe cough suppressant. Lyka has two formulations division and a bulk drugs division. It also set up additional manufacturing facilities for ointments. As part of its diversification, it has invested in Relic Finance, a company carrying on the business of finance and merchant banking.A GOI-recognised Export House, it received the Certificate of Merit for its excellent export performance in 1993-94. In the same year, it received an award from CHEMEXCIL for its outstanding performance.During 1997-98, the companys administrative office & plant at tarapur has been awarded ISO 9002 certification for its quality management... Read More


Reports by Lyka Labs Ltd


Reports by Lyka Labs Ltd

Company FAQ

No Record Found